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Neuroblastoma is the most common non-CNS tumor in
children. Poor prognosis for patients presenting with high-
risk disease underlines the need for novel therapeutic stra-
tegies. Chimeric antigen receptor T cell (CART) therapies
combine the epitope specificity of a monoclonal antibody
with the cytotoxicity of an activated T cell, and have
demonstrated clinical efficacy in pediatric leukemia. To
expand this approach to neuroblastoma, we focused on
anaplastic lymphoma kinase (ALK), which can exist in
native, over-expressed, or mutated forms and may help
drive disease progression. Single chain variable fragments
(scFvs) derived from four different monoclonal antibodies
against ALK were used to construct second-generation
CAR vectors featuring either CD28/CD3-zeta or CD137/
CD3-zeta signaling domains. Some CAR constructs also
included an IgG1 CH2CH3 spacer domain between the
scFv and transmembrane domain. Retroviral vectors
expressing ALK-specific CARs were generated and used to
transduce human peripheral blood mononuclear cells.
Transduction efficiencies ranged from 8% to 99%, depend-
ing on specific characteristics of each CAR construct. The
resulting CART lysed ALK-positive neuroblastoma and
Ewing’s sarcoma cell lines and had minimal activity against
an ALK-negative control. The ability to lyse tumor cells
varied across scFvs, and short CART (no Ig spacer)
showed enhanced lysis compared to long CARs (with
Ig spacer). Short CART also produced Th1 cytokines
(including IFN-gamma, IL-2, and TNF-alpha) when co-
incubated with ALK-positive tumor lines; however, long
CARs did not. Additionally, short anti-ALK CART signifi-
cantly delayed the growth of human neuroblastoma in an
NSG xenograft model when tumor-bearing mice were
preconditioned with cyclophosphamide. Ongoing
studies aim to: 1) further assess anti-ALK CART therapy
in vivo in combination with modulation of suppressive
murine myeloid populations; 2) explore mechanisms of
ALK-positive neuroblastoma resistance to CART-
mediated eradication; 3) characterize ALK protein
expression in murine central nervous system tissues to
better understand possibility of on-target, off-tumor
toxicities with this therapy. Ultimately, anti-ALK CART
could provide a novel therapy for pediatric solid tumors
expressing cell-surface ALK.
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